339792
3,4-Dibutoxy-3-cyclobutene-1,2-dione
98%
Synonym(s):
Dibutyl squarate
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
Recommended Products
Assay
98%
form
liquid
refractive index
n20/D 1.494 (lit.)
bp
139 °C/0.5 mmHg (lit.)
density
1.047 g/mL at 25 °C (lit.)
functional group
ether
SMILES string
CCCCOC1=C(OCCCC)C(=O)C1=O
InChI
1S/C12H18O4/c1-3-5-7-15-11-9(13)10(14)12(11)16-8-6-4-2/h3-8H2,1-2H3
InChI key
XBRWELTXMQSEIN-UHFFFAOYSA-N
Related Categories
General description
3,4-Dibutoxy-3-cyclobutene-1,2-dione is the dialkyl ester of squaric acid.
Application
3,4-Dibutoxy-3-cyclobutene-1,2-dione was used in the synthesis of novel semisquarylium dye, useful for highly selective Hg2+ sensing in aqueous media. It was also employed in the synthesis of 3-butoxy-4-(1,3,3-trimethyl-2,3-dihydro-1H-2-indolylidenemethyl)-3-cyclobutene-1,2-dione, intermediate for the synthesis of squaryl dyes.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
Target Organs
Respiratory system
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point(F)
235.4 °F - closed cup
Flash Point(C)
113 °C - closed cup
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Journal of drugs in dermatology : JDD, 5(3), 262-266 (2006-04-01)
Immunotherapy with sqauric acid dibutyl ester (SADBE) is a well-accepted therapy for alopecia areata. To study efficacy, safety, and factors influencing the outcome in the treatment of alopecia areata. During a 4-year period, 70 patients of alopecia areata, unresponsive to
Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies.
The Journal of dermatology, 29(10), 661-664 (2002-11-16)
Topical immunotherapy is effective for severe alopecia areata. However, there are patients with alopecia areata refractory to topical immunotherapy alone. We tried SADBE (squaric acid dibutylester) topical immunotherapy combined with topical dry ice cryotherapy, carpronium chloride (a parasympathetic nerve stimulant)
The Journal of dermatological treatment, 16(1), 10-14 (2005-05-18)
Severe alopecia areata (AA) may have a chronic relapsing course and is often resistant to current treatments. The aim of our study was to evaluate whether topical immunotherapy with squaric acid dibutylester (SADBE) is able to improve the course of
Journal of immunology (Baltimore, Md. : 1950), 179(8), 5071-5081 (2007-10-04)
Induction of a chronic eczema is a most efficient therapy for alopecia areata (AA). We had noted a reduction in regulatory T cells during AA induction and wondered whether regulatory T cells may become recruited or expanded during repeated skin
Toxicology and applied pharmacology, 183(1), 66-70 (2002-09-10)
The ability of chemical or pharmaceutical agents to induce allergic contact dermatitis (ACD) is of major health and regulatory concern. As such, tests to identify their sensitizing capacity, such as the guinea pig maximization test and the more recently developed
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service